The Technical Analyst
Enzon Pharmaceuticals, [ENZN]
Exchange: PNK Industry: Biotechnology
Enzon Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0750
America/New_York / 3 mai 2024 @ 09:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.57 mill |
| EPS: | -0.0100 |
| P/E: | -7.50 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 74.21 mill |
| Avg Daily Volume: | 0.0164 mill |
| RATING 2024-05-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.50 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -7.50 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0590 - 0.0910 ( +/- 21.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-16 | Read Randolph C | Buy | 84 550 | Common Stock |
| 2023-06-14 | Read Randolph C | Buy | 15 000 | Common Stock |
| 2022-06-09 | Firestone Jaffrey Adam | Buy | 0 | |
| 2021-08-13 | Couchman Jonathan | Sell | 57 500 | Common Stock, $0.01 par value |
| 2021-08-13 | Couchman Jonathan | Sell | 50 000 | Common Stock, $0.01 par value |
| INSIDER POWER |
|---|
| 100.00 |
| Last 86 transactions |
| Buy: 34 996 838 | Sell: 942 903 |
Forecast:
11:10 - $0.0760
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0750 (0.00% ) |
| Volume | 0.0007 mill |
| Avg. Vol. | 0.0164 mill |
| % of Avg. Vol | 4.28 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENZN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Latest Press Releases
2021-01-04 08:55:00 - Press Release
Enzon Pharmaceuticals, Inc. Ceo Andrew Rackear To Retire; richard L. Feinstein, Enzon's Cfo, To Assume Position Of Ceo And Remain Cfo
Cranford, n.j., jan. 04, 2021 (globe newswire) -- enzon pharmaceuticals, inc. (otc:enzn) announced today that andrew rackear has communicated to the board his intent to retire from his role as the company's chief executive officer effective february 26, 2021. andy joined enzon in 2010 as vice-president and general counsel and has served as ceo since 2016. upon andy's retirement, richard l. feinstein, enzon's chief financial officer, will also assume the role of chief executive officer and secretary, as well as remain the company's chief financial officer. mr. rackear will be available as a consultant to the company following his retirement, as may be needed.
Latest News
2022-11-29 20:30:22 - InvestorPlace
7 Undervalued Biotech Stocks to Buy Before They Boom
You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.
2021-01-04 08:55:00 - GlobeNewsWire
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company's Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy's retirement, Richard L. Feinstein, Enzon's Chief Financial Officer, will also assume the role of Chief Executive Officer and Secretary, as well as remain the Company's Chief Financial Officer. Mr. Rackear will be available as a consultant to the Company following his retirement, as may be needed.